Loading stock analysis…
Evidence Synthesis
Last synthesized: 5 Sept 2026, 03:58
See how this stock's evidence score moved across recent sessions — unlock Pro for the live chart.
Full momentum history unlocks with Pro or Research.
Evidence Synthesis
Here's a standard_shift narrative based on the provided payload: GlaxoSmithKline India Limited (GLCL) reported a quarterly earnings update on September 4, 2026, with key metrics indicating a strong performance.
Source observations behind the synthesis narrative.
| Metric | Value | Trend | |
|---|---|---|---|
| GROSS_MARGIN | 8.76 % | 4.64 | ▲ |
| MARGINAL_OPERATING_LEVERAGE | 4.64 % | 4.68 | ▼ |
| REVENUE_GROWTH_YOY | 443.9 % | -75.7 | ▲ |
| PRICE_CHANGE_PERCENT | 1.629 % | — | - |
| DAILY_VOLUME | 12,552 shares | 15,174 | ▼ |
| CLOSE_PRICE | 18.09 INR | 17.8 | ▲ |